콘텐츠로 건너뛰기
Merck
  • Inducible deletion of connexin 40 in adult mice causes hypertension and disrupts pressure control of renin secretion.

Inducible deletion of connexin 40 in adult mice causes hypertension and disrupts pressure control of renin secretion.

Kidney international (2014-09-18)
Melanie Gerl, Josef Vöckl, Birgül Kurt, Toon A B van Veen, Armin Kurtz, Charlotte Wagner
초록

Genetic loss-of-function defects of connexin 40 in renal juxtaglomerular cells are associated with renin-dependent hypertension. The dysregulation of renin secretion results from an intrarenal displacement of renin cells and an interruption of the negative feedback control of renin secretion by blood pressure. It is unknown whether this phenotype is secondary to developmental defects of juxtaglomerular renin cells due to connexin 40 malfunction, or whether acute functional defects of connexin 40 in the normal adult kidney can also lead to a similar dysregulation of renin secretion and hypertension. To address this question, we generated mice with an inducible deletion of connexin 40 in the adult kidney by crossing connexin 40-floxed mice with mice harboring a ubiquitously expressed tamoxifen-inducible Cre recombinase. Tamoxifen treatment in these mice strongly reduced connexin 40 mRNA and protein expression in the kidneys. These mice displayed persistent hypertension with renin expression shifted from the media layer of afferent arterioles to juxtaglomerular periglomerular cells. Control of renin secretion by the perfusion pressure was abolished in vitro, whereas in vivo plasma renin concentrations were increased. Thus, interruption of the connexin 40 gene in the adult kidney produced very similar changes in the renin system as had embryonic deletion. Hence, impairments of connexin 40 function in the normal adult kidney can cause renin-dependent hypertension.

MATERIALS
제품 번호
브랜드
제품 설명

Tamoxifen citrate for performance test, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Tamoxifen citrate salt, ≥99%
Sigma-Aldrich
Xylazine, ≥99%
Tamoxifen citrate, European Pharmacopoeia (EP) Reference Standard
Supelco
Tamoxifen, analytical standard
Sigma-Aldrich
Tamoxifen, ≥99%